EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514604-14-00

Enrollment

Registered

2024-06-11

Start date

2019-09-18

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle-invasive bladder cancer

Brief summary

The primary endpoint will be the pathological complete response defined as a response of grade 5 according to Miller and Payne criteria (Appendix 5) after the end of the treatment.

Interventions

DRUGTecentriq 1 200 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint will be the pathological complete response defined as a response of grade 5 according to Miller and Payne criteria (Appendix 5) after the end of the treatment.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026